Stereotaxis with new tech development
Shares of cardiology instruments systems manufacturer Stereotaxis, Inc. (Nasdaq: STXS) are sagging despite news the St. Louis, Mo.-based company has developed an innovative new interface.
“Odyssey” is a new product that consolidates multiple information sources and screens within an electrophysiology interventional lab into a single visual display, Stereotaxis said before the opening bell. The company said it hopes this will make it easier for physicians, who typically have to interact simultaneously with multiple systems and screens and diverse sources of diagnostic and imaging information during a procedure.
“Odyssey brings together all the different diagnostic information sources in an interventional electrophysiology lab, ranging from x-ray fluoroscopy, mapping systems and heart-rate monitoring systems, into a single display and networked user interface,” Stereotaxis CEO Bevil Hogg said. “This is the culmination of our drive to fully integrate our systems with the diagnostic information they rely on, while at the same time enabling remotely networked clinical support and training.”
The new system has already been installed at Stereotaxis’ clinical sites at San Raffaele University Hospital in Milan, Italy, and the University of Ottawa Heart Institute in Ottawa, Canada.
Installations of Odyssey will be connected worldwide to Stereotaxis’ remote Clinical Services Center in St. Louis, Mo. using IP Virtual Private Network (VPN) Service, a communications network created by Global Crossing Ltd. (Nasdaq: GLBC). Stereotaxis said this will allow Odyssey users to remotely share research and support clinical procedures, as well as to provide customers with on demand technical support and training at the touch of a button.
At 1:22 p.m. ET shares were down $0.03, or 0.28%, to $10.60. The 52-week high is $12.76, achieved on Feb. 23. The 52-week low of $8.14 was set on July 18, 2006.
“Odyssey” is a new product that consolidates multiple information sources and screens within an electrophysiology interventional lab into a single visual display, Stereotaxis said before the opening bell. The company said it hopes this will make it easier for physicians, who typically have to interact simultaneously with multiple systems and screens and diverse sources of diagnostic and imaging information during a procedure.
“Odyssey brings together all the different diagnostic information sources in an interventional electrophysiology lab, ranging from x-ray fluoroscopy, mapping systems and heart-rate monitoring systems, into a single display and networked user interface,” Stereotaxis CEO Bevil Hogg said. “This is the culmination of our drive to fully integrate our systems with the diagnostic information they rely on, while at the same time enabling remotely networked clinical support and training.”
The new system has already been installed at Stereotaxis’ clinical sites at San Raffaele University Hospital in Milan, Italy, and the University of Ottawa Heart Institute in Ottawa, Canada.
Installations of Odyssey will be connected worldwide to Stereotaxis’ remote Clinical Services Center in St. Louis, Mo. using IP Virtual Private Network (VPN) Service, a communications network created by Global Crossing Ltd. (Nasdaq: GLBC). Stereotaxis said this will allow Odyssey users to remotely share research and support clinical procedures, as well as to provide customers with on demand technical support and training at the touch of a button.
At 1:22 p.m. ET shares were down $0.03, or 0.28%, to $10.60. The 52-week high is $12.76, achieved on Feb. 23. The 52-week low of $8.14 was set on July 18, 2006.
About the Author
Reporter Alex Alexandrov is based in SmallCapInvestor.com's Washington, D.C. bureau.
Read More
(click a star)
Enter comment: